Mode
Text Size
Log in / Sign up
Phase 4 Completed N=43 Randomized Treatment

Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)

Kidney Failure, Chronic
Source: ClinicalTrials.gov NCT02933450 ↗
Enrolled (actual)
43
Serious AEs
0.0%
Results posted
May 2019
Primary outcomePrimary: Efficacy of Patiromer in Reducing Serum Potassium — 6.17; 6.6; 5.9; 6.47 mEq/L
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The Investigator hypothesize that a single dose of patiromer will lower serum potassium levels in less than 6hrs. Since a dosage of 30g/day for a period of 4 weeks has been studied in at least two multicenter randomized controlled trials, the Investigator further hypothesize that a single dose of 25.2g of patiromer will be well tolerated in hyperkalemic patients in the Emergency Department setting. The FDA approved dosage of 25.2g is appropriate for this study because the research staff will enroll patients with moderate (K greater than 6 mEq/L) to severe hyperkalemia, and the higher dosage has typically been used in this population for more effective control.

Outcome Measures

OutcomeResultp-value
PRIMARY
Efficacy of Patiromer in Reducing Serum Potassium
6.17; 6.6; 5.9; 6.47; 5.73; 6.04
SECONDARY
Tolerability of High Dose Patiromer in ESRD Patients on Hemodialysis in the Acute Setting.
4; 5; 1; 2; 3; 3

Eligibility Criteria

Inclusion Criteria

  • ESRD patients with serum potassium greater than or equal to 6.0 mEq/L
  • Emergent dialysis not expected to be available for 6 hours

Exclusion Criteria

  • new clinically significant arrhythmia on initial ECG
  • patiromer is contraindicated
  • have received SPS
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02933450). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search